Stockreport
Graft Versus Host Disease (GvHD) Treatment Industry Forecast Report, 2024-2032 - Global Market Size Forecast to Double, with Emerging Markets Offering Substantial Growth Potential [Yahoo! ...
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The graft versus host disease (GvHD) treatment market was valued at USD 2.55 billion in 2023. It is expected to grow at a CAGR of 8.50% during the forecast period of 2024-2032 and attain a value of USD 5.31 billion by 2032. It is driven by rising development of new therapeutic options, surge in clinical research, and growing awareness and diagnosis of GvHD across the 8 major markets. Future Opportunities Development of Targeted Therapies: The ongoing research into targeted therapies and personalised medicine offers significant growth opportunities. These treatments aim to improve efficacy and reduce side effects, providing better outcomes for patients. Expansion in Emerging Markets: Increasing healthcare infrastructure and rising awareness in emerging markets present substantial growth potential. Companies can focus on these regions to expand their market presence. Collaboration
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- Bank of America Turns Bullish on These 2 Lesser-Known Stocks [Yahoo! Finance][Yahoo! Finance]
- Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments [Yahoo! Finance][Yahoo! Finance]
- BMRN vs. INCY: Which Stock Is the Better Value Option? [Yahoo! Finance][Yahoo! Finance]
- Incyte Co. (NASDAQ: INCY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.[MarketBeat]
- More
INCY
SEC Filings
SEC Filings
- 11/8/24 - Form SC
- 11/8/24 - Form 4
- 11/6/24 - Form 144
- INCY's page on the SEC website
- More